Aberrant activation of plasmacytoid dendritic cells ( pDCs) with excessive production of interferon alpha (IFNα) represents one of the hallmarks of immune activation during chronic phase of human immunodeficiency virus (HIV) infection. A number of studies have shown that disruption of mucosal integrity in the gut is a cause of persistent immune activation. However, little is known about the role that pDCs play in this process, and our current understanding comes from the simian immunodeficiency virus macaque model. Thus, in the present study we sought to investigate the frequency and function of pDCs in peripheral blood and gut samples from HIV-infected individuals before and 6 months after initiation of antiretroviral therapy (ART). We show that circulating pDCs were depleted in ART-naive HIV+ patients, and upregulated the gut-homing receptor CD103 compared with uninfected controls. By converse, pDCs accumulated in the terminal ileum of ARTnaive HIV individuals compared with controls. Baseline levels of IFNα production and markers of immune activation in gut samples of ART-naive HIV subjects were elevated. All these parameters declined after 6 months of ART. Our results suggest that in chronic HIV infection, pDCs migrate from peripheral blood to the gut-associated lymphatic tissue, where they may contribute to immune activation.
The appearance of the proinflammatory cytokine, interferon alpha (IFNα), in the serum of human immunodeficiency virus (HIV)-infected individuals is associated with disease progression, and has been implicated as a cofactor in chronic immune activation [1, 2] . Plasmacytoid dendritic cells ( pDCs) are innate immune cells that respond to microbial infection by producing large amounts of IFNα [3] . During HIV infection, pDCs decline in peripheral blood (blood) [4] [5] [6] [7] , and relocate to peripheral lymph nodes where they produce high levels of IFNα [8] [9] [10] .
The gastrointestinal mucosa (gut-associated lymphatic tissue, GALT) represents the largest lymphoid organ and harbors the majority of the body's lymphocytes [11] . Severe damage and abnormalities of the intestinal epithelial barrier have been described in HIV-infected patients, even in early stages of disease [12] . A recent study provided evidence for pDCs being rapidly recruited to the colorectum after pathogenic simian immunodeficiency virus (SIV) infection in rhesus macaques. These pDCs produced IFNα and other proinflammatory cytokines, causing immune activation in colorectal tissue [13] . The consequences of local mucosal damage of the intestine and the coherence with systemic immune activation in HIV-infected individuals have been described [14] , particularly an increased permeability to microbial products such as lipopolysaccharide (LPS) that exit the gastrointestinal lumen and reach the bloodstream [15] . The levels of LPS found in plasma of HIV patients are sufficiently high to induce inflammatory responses [16, 17] .
Indeed, the dynamics of pDCs, IFNα production, and chronic immune activation appear to be interrelated in HIV infection. Plasma levels of LPS and IFNα closely correlate in HIV patients [15] .
So far, little is known about the distribution and function of pDCs in the intestinal mucosa of HIV-infected patients, and the majority of our current understanding is resulting from the SIV-macaque model. Therefore, our study sought to address the hypothesis that in the course of chronic HIV infection, peripheral pDCs migrate to the GALT where they contribute to immune activation. For the first time, we report a longitudinal study analyzing the frequency and steady-state IFNα secretion of pDCs as well as LPS levels in the GALT and blood of HIV-1 patients before and after the initiation of antiretroviral therapy (ART).
PATIENTS AND METHODS

Study Design
This prospective longitudinal study was carried out in 3 Departments of Internal Medicine at the University of Cologne and the Center for HIV and Hepatogastroenterology Düssel-dorf, Germany. After informed consent, 30 HIV-infected adults meeting entry criteria were recruited. Inclusion criteria comprised: (1) age 18-65 years, (2) infection with HIV-1, and (3) naive to ART. Exclusion criteria were: (1) hepatitis B or C co-infection, and (2) clinical contraindications for sedation or endoscopy. Endoscopic biopsies and blood samples were obtained before starting ART and 6 months thereafter. Standard treatment according to international guidelines was applied. In addition, 15 healthy HIV negative individuals served as controls. All individuals had to be free of inflammatory or lymphoproliferative bowel diseases on histopathologic examination. The study was approved by the Institutional Review Board of the University of Cologne, Germany (09-210). Clinical Trial Registry Number Identifier (ClinicalTrials.gov): NCT 01679067.
Phlebotomies (50 mL blood) were undertaken immediately before endoscopy. An amount of 1-2 × 10 6 peripheral blood mononuclear cells (PBMCs) isolated by Ficoll-Hypaque density gradient were set aside for flow cytometry, while the remainder was divided and frozen at −80°C for subsequent DNA or RNA extraction. Plasma and serum were frozen until use. Endoscopic biopsies were obtained from the terminal ileum and immediately placed in tissue culture medium or in formalin.
Isolation of Gut Cells
Six to 10 biopsies from each site were separated into single cells using the method by Shaklett et al [18] with minor modifications. Briefly, biopsies were subjected to 3 rounds of collagenase digestion, mechanical disruption ( passage through a blunt 16-gauge needle), clarification (70-µm cell strainer), and washing. An amount of 1-2 × 10 6 cells were set aside for flow cytometry; the remainder was divided and frozen at −80°C for subsequent RNA extraction. HIV plasma viral load was quantified using Roche Amplicor kits (Roche Diagnostics) with a lower limit of detection of 40 copies/mL. Levels of LPS in plasma and IFNα in serum were quantified by the limulus amebocyte assay (Hycultec, Netherlands) and enzyme-linked immunosorbent assay (PBL Biomedical Laboratories, Piscataway, NJ).
Immunophenotyping
In brief, fresh PBMCs and lymph node mononuclear cells (LNMCs) were incubated with the following antibodies and appropriate isotype controls: anti-CD123-APC (clone REA114) and BDCA2-FITC (clone AC144) (Miltenyi Biotec, Germany), CD3-APC (clone HIT3a), CD4-FITC (clone L200), CD8-FITC (clone HIT8a), CD38-PE (clone HIT2), HLA-DR-Percp (clone G46-6), and CD103-PE (clone Ber-ACT8) (BD Bioscience). Cells and data were analyzed by flow cytometry (FACSCanto1) using FACSDiva software (BD Biosciences) and FlowJo software (Tree Star, Ashland, OR).
RNA Extraction and Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted (Roche Diagnostics) from PBMCs and 1 × 10 6 cells from the terminal ileum. Quantitative MxA expression (LightCycler, Roche Diagnostics) was performed as previously described [19] . 
RESULTS
We obtained ileal biopsies from 30 HIV-infected patients and 15 healthy controls. The demographic and clinical characteristics of HIV-infected individuals and controls (all white individuals) are summarized in Table 1 . All HIV-infected patients were ART naive at the time of sample collection, and ART was started after the colonoscopy. Eleven of the HIV-infected persons were examined by colonoscopy 6 months after initiation of ART. Out of these 11 patients, 7 had a protease inhibitor-based regimen, and 4 had a nonnucleoside reverse trancriptase inhibitor-based regimen. Median viremia of HIV-infected patients was 136 500 copies of HIV-RNA/mL (IQR, 25 858-574 674). All 11 patients who completed the 6-month study achieved virologic control in plasma to less than 40 copies/mL. In contrast, only 6 of 11 patients achieved clearance of viremia in the GALT, with HIV-RNA decreasing from 4.2 (IQR, 3.3-4.5) log 10 copies/100 000 CD4 + T cells to less than 1.6 log 10 copies/100 000 CD4 + T cells Figure 1D ). The CD4/CD8 ratio in the GALT from controls was 1.8 (IQR, 1.3-3.5). In HIV-infected subjects, the CD4/CD8 ratio in the GALT increased from 0.4 (IQR, 0.1-0.7) to 0.9 (IQR, 0.4-1.5) after 6 months of ART (P = .04, Figure 1E ). Due to insufficient biopsies, we were unable to assess absolute numbers of immune cells in microscopic immunohistochemistry sections for most of our patients post ART. Thus, the interpretation of our data is focused on the longitudinal changes in the frequency of respective cells as determined by flow cytometry.
pDCs Relocate From Peripheral Blood to the Gut Mucosa During Chronic HIV Infection
We analyzed the frequency of pDCs in GALT and blood from HIV-infected individuals compared with healthy controls. HIV-1-positive subjects show a significantly higher percentage of pDCs in GALT than in blood (P = .0014), whereas in controls the converse occurs (P < .0019). The median percentage of pDCs in GALT of HIV-infected patients was 0.5 (IQR, 0.2-0.8) versus 0.3 (IQR, 0.2-0.6) in controls (see Figure 2A) . Comparing their frequency in blood of HIV-infected patients before and after 6 months on ART, pDCs increased significantly (P = .008) up to levels similar to those of healthy individuals. In 
To further validate the evidence that during HIV-1 infection pDCs relocate from blood to the GALT, we assessed the expression of CD103 on peripheral pDCs in HIV-positive and -negative individuals. CD103 has been previously shown to mediate trafficking and retention of T cells in the gut mucosa [20, 21] . Circulating pDCs of HIV-infected patients express higher levels of the gut-homing receptor CD103 compared with controls (geometric mean fluorescence intensity, GMFI; 15 [IQR, 12-21] vs 10 [IQR, 7-15]; P = .007; Figure 2D ). In addition, we sought to visualize the accumulation of pDCs in the gut mucosa during HIV infection. To this end, we performed immunohistochemistry of CD123 + cells in ileal biopsy sections [22] . Figure 2C ). controls, we found 5-fold and 2-fold higher MxA mRNA levels in ileal biopsies and PBMCs, respectively, of ART-naive HIVinfected patients ( Figure 3B ). However, MxA expression normalized upon initiation of ART (HIV+ naive vs treated: P = .012; treated vs controls: P = .3412 Figure 3B ). Finally, we found a positive correlation between plasma IFNα levels and frequency of ileal pDCs (r = 0.53; P = .01 Figure 3G ), suggesting that GALT-homed pDCs of HIV-infected patients secrete excessive amounts of IFNα. High frequency of CD4 + and CD8 + T cells expressing the immune "activation" markers CD38 and human leukocyte antigen (HLA)-DR is associated with poor prognosis [26, 27] .
We assessed the coexpression of CD38 and HLA-DR on CD8 + T cells of the GALT and compared it to blood. In all groups, the frequency of HLA-DR + CD38 + CD8 + T cells was higher in blood compared with the GALT (blood vs GALT naive: P = .018; ART: P = .015; control: P = .012). In HIV-infected naive individuals, the frequency of HLA-DR + CD38 + CD8+ T-cells was higher in both compartments compared to controls and HIV-1-positive subjects on ART ( Figure 3A) . Interestingly, MxA mRNA in the GALT correlated positively with the expression of CD38 and HLA-DR on CD8 + T cells in the GALT (r = 0.49; P = .023; Figure 3F ). Translocation of microbial products (eg, LPS) as well as high IFNα serum levels are associated with systemic immune activation observed during HIV-1 infection [15] . Thus, we assessed the levels of LPS and IFNα in blood of HIV-infected subjects and controls. Median plasma concentration of LPS was higher in therapy-naive HIV-infected individuals than in uninfected controls (4.5 EU/mL [IQR, 2.8-11] vs 3 EU/mL [IQR, 2.5-3.2]; P = .02). We also measured higher levels of IFNα in serum of HIV-1-positive subjects compared with uninfected individuals (74.02 pg/mL [IQR, 46.6-86.43] vs 52.8 pg/mL [IQR, 33.4-57.2]; P = .0087). Of note, we found a positive correlation between plasma LPS concentrations with MxA expression in the GALT (r = 0.45; P = .02, Figure 3E ) only in HIV-infected naive patients. Upon initiation of ART, the concentrations of LPS and IFNα declined (treatment-naive vs treatment experienced P = .03 and P < .001, respectively; Figure 3C and 3D) . Indeed, the plasma levels of LPS returned to those observed in uninfected individuals (P > .05; Figure 3C ), whereas serum IFNα levels dropped significantly below those found in healthy controls (P = .02; Figure 3D ).
DISCUSSION
This is the first prospective, longitudinal study and comparative analysis of pDC distribution and function in the GALT and blood of HIV-infected individuals before and after initiation of ART. Our main findings are that pDCs relocate from blood to the GALT in chronic HIV infection. The high frequency of pDCs in the GALT correlates positively with IFNα expression and an activated phenotype of CD8 + T cells, indicating an immuneinductive environment.
In a previous study, we concluded that the repeatedly reported decline of pDCs in blood of HIV patients [5, 7, 28] is due to trafficking and redistribution of pDCs from peripheral blood to lymph nodes rather than to systemic loss during the chronic phase of HIV infection [10] . Because the same study revealed that circulating pDCs of HIV-infected patients express higher levels of the gut-homing marker CD103, we hypothesized that pDCs would also accumulate in the GALT, the largest lymphoid tissue. Indeed, biopsies from the GALT of therapy-naive HIV-infected subjects showed a significantly higher frequency of pDCs compared with biopsies from healthy controls. As described previously [5, 7, 28] , circulating pDCs were reduced in our HIV-infected therapy-naive group. These data from HIV-1-positive individuals are in line with 2 recent animal studies in a pathogenic SIV infection model also showing higher frequencies of pDCs in GALT compared with blood of infected animals [13, 29] .
After 6 months on ART, the frequency of pDCs in blood normalized to levels of healthy individuals. In contrast, the percentage of pDCs in the GALT did not decline to normal values, indicating an incomplete reconstitution of the gut mucosa. Upon ART treatment, Kwa et al observed a decline of pDCs in the colorectum of SIV-infected rhesus macaques. Their specimens, however, were primarily obtained from the colorectum, whereas we analyzed biopsies from ileum where the density of Peyer's patches is much higher than in the colorectum.
We thought of incomplete virological suppression of HIV in GALT as a possible reason for persistence of pDCs in the GALT. Though, when differentiating between "gut virological responders" and "gut nonresponders," there was no association of response and frequency of pDCs (data not shown). Moreover, an expanded enteric virome as it has been described in pathogenic SIV infection [30] may also contribute to the migration of pDCs to the GALT.
Consistent with the evidence that pDCs of HIV-1 subjects relocate from blood to the GALT, we show that circulating pDCs of HIV-infected patients express higher levels of CD103 (also known as integrin αE), which-in complex with integrin β7-mediates cell redistribution to the intraepithelial sites and lamina propria of the GALT. Of note, expression of CD103 declined upon initiation of ART. Kwa et al observed upregulation of integrin β7 on pDCs in SIV infection, but no increase in CD103 expression [13] . Instead, they found coexpression of CD49 (α4), indicating the heterodimer expressed was α4β7 and not αEβ7. Moreover, they found upregulation of β7-integrin on pDCs derived from chronically HIV-infected patients. This observation-taken together with our finding of significant upregulation of integrin αE on pDCs from our therapy-naive individuals-suggests that, in humans, αEβ7 has a possible role in trafficking of peripheral pDCs to the GALT. Concentrations of LPS (C) and IFNα (D) in plasma or serum obtained from HIV-infected individuals before (n = 30) and after 6 months of ART (n = 11) and from uninfected individuals (n = 15). Plasma LPS was measured by the Limulus amebocyte lysate assay. Serum IFNα was quantified using ELISA. The limit of detection was 0.01 EU/mL and 12.5 pg/mL, respectively. Spearman correlations: (E) between LPS in plasma and MxA RNA expression in GALT; (F) between immune activated phenotype in GALT (expression of HLA-DR + CD38 + on CD8 + T cells) and MxA RNA expression in the GALT; (G) between plasma IFNα and pDC frequency in the GALT. Abbreviations: ART, antiretroviral therapy; ELISA, enzyme-linked immunosorbent assay; GALT, gut-associated lymphatic tissue; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GMFI, geometric mean fluorescence intensity; HIV, human immunodeficiency virus; HLA-DR, human leukocyte antigen-DR; IFNα, interferon alpha; IQR, interquartile range; LNMCs, lymph node mononuclear cells; LPS, lipopolysaccharide; PBMCs, peripheral blood mononuclear cells; PCR, polymerase chain reaction; pDCs, plasmacytoid dendritic cells.
of ART suggests a role for pDC recruitment to the GALT in disease progression.
A possible causative link between increased IFNα expression, chronic immune activation, and HIV disease progression was suggested by the fact that after ex vivo exposure to IFNα, CD8 + T cells of HIV subjects express significantly more CD38 compared with uninfected individuals [2] . In our study, we show relocation of pDCs from blood to the GALT. In the GALT, these pDCs secrete excessive amount of IFNα, which is biologically active as indicated by an increased expression of MxA. This activity correlates positively with an activated phenotype of CD8 + T cells in the GALT. As also reported by others [31] [32] [33] , we found that the frequency of HLA-DR + CD38 + CD8 + T cells was higher not only in the GALT but also in blood of HIV-infected naive individuals compared with controls and longitudinally declined upon initiation of ART. This activated phenotype correlated with overexpression of MxA in the GALT and blood as well as with plasma levels of LPS in HIV-infected patients. The positive correlation of IFNα/MxA expression in the GALT with microbial translocation, the presence of LPS in blood, indicates that the mucosal barrier in HIV-positive naive subjects is not intact. The role of LPS in serum as a surrogate marker for the loss of mucosal integrity [34, 35] is reviewed in [36] .
Brenchley et al showed a positive correlation of IFNα levels, LPS plasma levels, and the presence of activated CD8 + T cells (CD38 + HLA-DR + ) in chronically infected HIV patients [15] .
A microarray analysis of in vivo-activated CD4 + T cells from chronically infected HIV patients showed that hyperproliferating CD4 + T cells had an IFNα signature [37] . Furthermore, Estes et al demonstrated that IFNα colocalizes with bacterial components in lymphoid tissues of SIV-infected macaques [38] . Taken together, these data imply that not only the loss of CD4 + T cells but also the persistent release of proinflammatory IFNα by pDCs in the GALT of patients with chronic HIV infection contributes to enteropathy with the loss of mucosal integrity, thereby leading to microbial translocation, which in turn promotes chronic immune activation.
Aside from the infiltration of pDCs, the composition of immune cells in the GALT changes remarkably in the course of HIV infection [32, 39] . We found a significant depletion of CD4 + T cells in the GALT compared with HIV-negative individuals. In contrast, the infiltration of CD8 + T cells in the GALT was markedly higher in untreated chronic HIV-infected patients compared with HIV-negative subjects. After 6 months on ART, blood CD4 + T cells increased from 15% to 25%, whereas CD4 + T cells in GALT only increased from 10% to 14%. Also, the CD8 + T-cell frequency did not decline to values observed for healthy controls. Moreover, among the patients who completed the 6-month study, only 6 out of 11 achieved virologic control in GALT (<40 copies/CD4 + T cells). In healthy, HIV-uninfected individuals, approximately 40% of lymphocytes in GALT are CD4 + T cells [40, 41] . In accordance with a very recent publication, the ileal reconstitution of CD4 + T cells after 6 months on ART is insufficient [42] . Possible reasons for such partial immune recovery in the GALT of HIV-infected subjects on ART include damaged tissue architecture and deposition of collagen [42, 43] as well as low-level HIV-1 replication in the GALT [44] [45] [46] . This is the first study in humans reporting that in untreated HIV infection pDCs relocate from peripheral blood to the gut mucosa, the primary site of virus replication. Moreover, we report increased MxA expression-a surrogate marker of IFNα production-in the GALT of untreated HIV-1 subjects compared with uninfected individuals. After 6 months on ART, we observed only partial restoration of normal pDC frequency in GALT of infected individuals, whereas MxA expression declined to normal levels. The composition of immune cells in the GALT is also characterized by predominance of CD8 + T cells exhibiting an activated phenotype. We propose that these events promote local inflammation of the gut mucosa, leading to a loss of mucosal integrity and subsequent bacterial translocation. The latter drives systemic immune activation among other mechanisms by the proinflammatory effects of LPS [47] . And finally, the excessive local release of IFNα in the GALT refuels serum levels of biologically active IFNα, thereby directly contributing to immune activation. However, a distinct causeeffect relationship between IFNα, microbial translocation, and chronic immune activation remains to be established.
Notes
